FDA Fast Tracks Gene Therapy for X-Linked Retinitis Pigmentosa … – Monthly Prescribing Reference
|
FDA Fast Tracks Gene Therapy for X-Linked Retinitis Pigmentosa …
Monthly Prescribing Reference The Food and Drug Administration (FDA) has granted Fast Track designation to AAV-RPGR (MeiraGTx Limited), a gene therapy candidate intended for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase … |
